From Fast Follower To Innovator: Korea Capturing Global Pharma Interest
KHIDI president Soon-Do Cha talks to Scrip about why South Korea’s significance as a global partner is rising, what’s driving recent platform deals, and the government agency’s breadth of support for Korean companies.
Scrip - June 5, 2026

ADA 2026: Implantables, Interoperability, And AI Signal A CGM Market In Transition
Next-gen algorithms, 3-year implantable sensors, and AI agents redefine diabetes tech. A look at key device innovations debuting in New Orleans.
Medtech Insight - June 5, 2026

US Consumer Health Industry News Digest: Business, Regulation, Science
Weekly digest: NIH studies kratom for opioid addiction; Kentucky representative readies bill to help hemp industry; Mexico firm’s topical OTCs on import alert; final June deadline for OMUFA facility fees; C&D, P&G executives make investor rounds in Paris.
HBW Insight - June 5, 2026

Canada Drops Need For Biosimilar Comparative Clinical Efficacy Studies
Health Canada's elimination of comparative clinical efficacy studies for biosimilar products aligns with steps being taken by the US and EU drug regulators.
Generics Bulletin - June 4, 2026

US Supreme Court Backs Hikma In Landmark Skinny-Label Generic Ruling
In a long-awaited ruling over skinny-label generic carve-outs and induced infringement, the US Supreme Court has come down on the side of the generics industry by backing Hikma over Amarin in the culmination of the pair’s long-running litigation over Vascepa.
Generics Bulletin - June 4, 2026

Hikma Overtakes US Xeljanz Exclusivity As Tablets Loom Larger
Hikma’s launch of a generic version of Xeljanz oral solution, though small in scale, highlights Slayback’s first-filer status, widening generic competition and the much bigger tablet opportunity now opening up.
Generics Bulletin - June 4, 2026

Endo Creditors Fight On In $4bn Par-TPG Dispute
A bankruptcy judge has let Endo’s trustee keep pursuing Par’s former owner TPG over allegations that Endo significantly overpaid for Par in 2015, while dismissing opioid contribution claims and claims against former Par executives.
Generics Bulletin - June 4, 2026

ASCO 2026: Standout Wins And Strategic Shifts
Revolution Medicines' PDAC survival data headlined the recent ASCO meeting, alongside practice-changing readouts from J&J and Lilly, a crowded ADC and bispecific field, and Chinese biotechs delivering increasingly competitive results.
In Vivo - June 4, 2026

The CEO Who Wants to Make Tacrolimus History
Eledon CEO David-Alexandre Gros is advancing tegoprubart, a CD40L blocker showing dramatically fewer side effects than tacrolimus, toward Phase III kidney transplant trials and beyond.
In Vivo - June 4, 2026